ICD 10 CM C86.5 | Description & Clinical Information

ICD 10 C86.5 describes a form of non-Hodgkin lymphoma known as angioimmunoblastic T cell lymphoma (AITL), which is characterized by the abnormal multiplication of T cell lymphocytes and is typically rare and aggressive, with a higher incidence in older patients.

Official Description Of C86.5

The ICD 10 CM book defines ICD 10 code C86.5 as:

When To Use C86.5

The diagnosis describes by the ICD 10 CM C86.5 code is angioimmunoblastic T-cell lymphoma (AITL), a rare type of non-Hodgkin’s lymphoma. The disease primarily affects older adults, but it can occur in people of all ages.

Patients with AITL often experience painless, enlarged lymph nodes of multiple sites, along with other troubling symptoms such as frequent infections, itching, and easy bruising and bleeding. Some patients may also develop B symptoms, which include night sweats, pain, relapsing/remitting fever, and weight loss.

The condition can also cause damage to red blood cells resulting in hemolytic anemia and a decreased number of red cells, which can lead to fatigue and shortness of breath. Additionally, patients with AITL may suffer from thrombocytopenia, which impairs the ability of the blood to clot.

Diagnosing AITL requires a careful analysis of the patient’s medical history, physical examination, and laboratory results. Healthcare providers typically conduct a lymph node biopsy to obtain a tissue sample, which is then analyzed under a microscope. Additional diagnostic procedures include a complete blood cell count (CBC), liver function tests, kidney function tests, and lactate dehydrogenase (LDH) test.

Imaging tests like computed tomography (CT) scans or positron emission tomography (PET) scans can help determine the extent of the malignancy and stage the disease. Once the diagnosis is confirmed, healthcare providers will determine the best course of treatment for the specific patient.

The treatment plan for AITL depends on the stage and severity of the disease. For patients with mild symptoms, high-dose steroids can be prescribed to help reduce inflammation and suppress the immune system. In more severe cases, chemotherapy is typically recommended, especially if the lymphoma is advanced. The most common chemotherapy regimen for AITL is called CHOP, which stands for cyclophosphamide, doxorubicin, vincristine, and prednisone.

In some cases, patients may also benefit from stem cell transplantation, which involves replacing damaged or destroyed bone marrow with healthy stem cells. The treatment aims to help rebuild the immune system and increase the patient’s overall survival rate.

It’s important to note that every patient is unique, and there’s no one-size-fits-all approach to treating AITL. The goal is always to provide the most effective care while minimizing the risk of side effects or complications.

In conclusion, angioimmunoblastic T-cell lymphoma is a rare and complex disease that requires careful diagnosis and targeted treatment. Healthcare providers must remain vigilant when assessing patients for AITL and use a variety of diagnostic tests to confirm or rule out the diagnosis. With proper treatment and care, patients with AITL can achieve remission and experience a good quality of life.